New Drug Approvals: October 2006

Date of Approval: October 5, 2006

Company: GlaxoSmithKline

Treatment for: Influenza Prophylaxis

FluLaval (Influenza Virus Vaccine) is indicated for the active immunization of adults 18 years and older against influenza disease caused by influenza virus types A and B contained in the vaccine.

Date of Approval: October 6, 2006

Company: Sepracor Inc.

Treatment for: Chronic Obstructive Pulmonary Disease

Brovana (arformoterol tartrate) is a long-acting beta2-agonist for inhalation via a nebulizer, used for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Date of Approval: October 6, 2006

Company: Merck & Co., Inc.

Treatment for: Cutaneous T-cell Lymphoma

Zolinza (vorinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin's lymphoma, who have progressive, persistent or recurrent disease on or following two systemic therapies.

New Indication Approved: October 6, 2006

New Indication Approved: October 11, 2006

New Indication Approved: October 11, 2006

Date of Approval: October 17, 2006

Company: Merck & Co., Inc.

Treatment for: Diabetes Mellitus Type II

Januvia (sitagliptin phosphate) is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

Date of Approval: October 20, 2006

Company: SkinMedica, Inc.

Treatment for: Dermatitis

Desonate (desonide) is a low potency topical steroid formulated in a proprietary water- based Hydrogel vehicle indicated for the treatment of mild to moderate atopic dermatitis.

Date of Approval: October 20, 2006

Company: Altana Pharma

Treatment for: Allergic Rhinitis

Omnaris (ciclesonide) is an intranasal corticosteroid indicated for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 12 years of age and older.

New Indication Approved: October 20, 2006

Date of Approval: October 25, 2006

Company: Novartis

Treatment for: Chronic Hepatitis B

Tyzeka (telbivudine) is a synthetic thymidine nucleoside analogue indicated for the treatment of chronic hepatitis B.

Date of Approval: October 27, 2006

Company: Artes Medical, Inc.

Treatment for: Facial Wrinkles

ArteFill is a dermal filler indicated for the correction of nasolabial folds, or smile lines.

Date of Approval: October 31, 2006

Company: MediGene AG

Treatment for: Condylomata Acuminata

Veregen(kunecatechins) contains a concentrate of catechines extracted from green tea leaves. Veregen is indicated for the treatment of external genital and perianal warts.